Trial · NCT01295827
Adverse events5,652
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 5,652
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A) | 1 | 4 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1) | 0 | 10 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2) | 0 | 4 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2) | 0 | 3 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2) | 0 | 6 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D) | 27 | 162 | 58 |
| other | Anaemia | Blood and lymphatic system disorders | MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D) | 61 | 313 | 113 |
| other | Anaemia | Blood and lymphatic system disorders | MEL: Pembrolizumab 10 mg/kg Q2W (Part B) | 30 | 180 | 57 |
| other | Anaemia | Blood and lymphatic system disorders | NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F) | 5 | 61 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F) | 37 | 287 | 52 |
| other | Anaemia | Blood and lymphatic system disorders | NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F) | 38 | 202 | 72 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A) | 0 | 4 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A) | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1) | 1 | 10 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2) | 0 | 4 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2) | 0 | 3 | 0 |
| other | Atrial fibrillation | Cardiac disorders | Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2) | 0 | 6 | 0 |
| other | Atrial fibrillation | Cardiac disorders | MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D) | 2 | 162 | 2 |
| other | Atrial fibrillation | Cardiac disorders | MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D) | 7 | 313 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01295827/events